Shield Therapeutics appoints new CEO as it prepares for American launch of Accrufer

  • Shield Therapeutics inks licence agreement for Accrufer in South Korea
  • Shield Therapeutics says OTCQX Best Market listing ahead of Accrufer US launch has ‘great potential’
Shield Therapeutics PLC -

Quick facts: Shield Therapeutics PLC


View company profile

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru(R)/Accrufer(R), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru(R)/Accrufer(R) has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.

12 Aug 2021

(, ) said it has secured a licence agreement in South Korea for its Accrufer iron deficiency therapy.

Under the deal with Korea Pharma Co Ltd, the company said it will receive an upfront payment of GBP0.5mln and is also eligible to receive a further GBP1.5mln upon the first commercial sale of Accrufer in Korea.

Shield said it will also receive up to GBP4mln in milestone payments upon the achievement of specified cumulative sales targets, as well as royalties of 15% on net sales of Accrufer for the duration of the intellectual property in Korea.

The firm added that Korea Pharma will cover all clinical and regulatory costs and activities as well as all manufacturing and distribution costs of goods sold in Korea.

Read more

09 Aug 2021

(, ) () has flagged up research in a leading academic publication showcasing some “very exciting” results from a study involving its lead product.

Investigators assessed the potential of Feraccru (known as Accrufer in the US, and also called ferric maltol).

Read more

24 Jun 2021

() confirmed it will launch its Accrufer product in the US on 1 July.

The pharmaceutical company, which focuses on addressing iron deficiency, said launch stocks are currently being distributed through the wholesaler channels and will be available to doctors and other prescribers in all parts of the US.

Read more

17 May 2021

‘s (, OTCQX:SHIEF), Tim Watts talks to Proactive London about their new US stock market quote on the OTCQX Best Market.

This decision is to support the upcoming launch of Accrufer in the US with the aim to increase relevance to US-based investors.

Watts explains that they will face no additional reporting requirements as a result of the American listing, therefore the additional costs will be ‘minimal’.

11 Mar 2021

STX is preparing to launch prescription iron replacement treatment Accrufer in the US, a market estimated to be worth US$1.2bn pa, the largest global market for iron replacement treatment. A self-launch can provide STX with the lion’s share of projected profits, peak sales estimate of up to US$400mln by year six, and is timely given the opportunity to gain traction given the unmet need for a well-tolerated, effective and convenient treatment for Iron Deficiency (ID). STX estimates that funding of US$40mln (GBP29mln) will enable it to rapidly ramp up revenues, sufficient to reach break-even at the 18-month point. The projected strategy, 90% margin product profile and promising conclusions from market research with top ten US payers suggest the potential for significant cash generation. The US launch on its own, if executed in line with STX’s internal projections, can more than justify the market capitalisation of the company, even applying conservative projections.

Read full report

Download Research

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…


Shield Therapeutics’ get to work ahead of US launch of Accrufer in June

Shield Therapeutics PLC (LON:STX) Tim Watts updates investors on its track to launch Accrufer, its iron deficiency treatment, in the US by the end of next month.

Preparatory work on the launch has accelerated dramatically, the firms has established a US subsidiary and set up the necessary…

on 21/5/21

3 min read


Please enter your comment!
Please enter your name here